[1]郑晓芳.药物联合PCI治疗冠状动脉临界狭窄预后及其与血浆hs-CRP、IL-6、IL-8、血浆纤维蛋白原的相关性研究[J].医学信息,2018,31(13):112-114.[doi:10.3969/j.issn.1006-1959.2018.13.033]
　ZHENG Xiao-fang.Effect of Combined PCI on Prognosis of Coronary Artery Stenosis and its Correlation with Plasma hs-CRP,IL-6,IL-8 and Plasma Fibrinogen[J].Journal of Medical Information,2018,31(13):112-114.[doi:10.3969/j.issn.1006-1959.2018.13.033]
点击复制

药物联合PCI治疗冠状动脉临界狭窄预后及其与血浆hs-CRP、IL-6、IL-8、血浆纤维蛋白原的相关性研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年13期
页码:
112-114
栏目:
临床研究
出版日期:
2018-07-01

文章信息/Info

Title:
Effect of Combined PCI on Prognosis of Coronary Artery Stenosis and its Correlation with Plasma hs-CRP,IL-6,IL-8 and Plasma Fibrinogen
文章编号:
1006-1959（2018）13-0112-03
作者:
郑晓芳
江西鹰潭市人民医院内一科，江西 鹰潭 335000
Author(s):
ZHENG Xiao-fang
Department of Internal Medicine,Subject One,People’s Hospital,Yingtan 335000,Jiangxi,China
关键词:
冠状动脉临界狭窄; 药物; PCI; 炎性因子; 凝固因子
Keywords:
Key words：Coronary artery stenosis; Drugs; PCI; Inflammatory factors; Coagulation factors
分类号:
R543.3
DOI:
10.3969/j.issn.1006-1959.2018.13.033
文献标志码:
A
摘要:
目的 分析药物联合PCI治疗冠状动脉临界狭窄对患者血浆高敏hs-CRP、IL-6、IL-8、血浆纤维蛋白原表达的影响。方法 将在我院接受药物治疗的29例冠状动脉临界狭窄患者设为对照组，将在我院接受药物联合PCI治疗的30例冠状动脉临界狭窄患者设为研究组，检测两组患者治疗前后的血浆hs-CRP、IL-6、IL-8、纤维蛋白原表达水平。结果 治疗后，研究组患者血浆hs-CRP、IL-6、IL-8、纤维蛋白原表达水平低于对照组，差异具有统计学意义（P＜0.05）。研究组住院期间和出院后1年内的心血管不良事件发生率分别为3.33%和6.67%，低于对照组的20.69%和27.59%，差异具有统计学意义（P＜0.05）。结论 药物联合PCI治疗冠状动脉临界狭窄，能够有效降低患者血浆中炎性因子和凝固因子的表达水平，有利于临床进一步改善该疾病患者的预后。
Abstract:
Abstract：Objective To analyze the effect of drug combined with PCI on coronary artery stenosis on plasma high-sensitivity hs-CRP, IL-6,IL-8 and plasma fibrinogen expression.Methods 29 patients with coronary artery stenosis who were treated with drugs in our hospital were enrolled in the control group.30 patients with coronary artery stenosis who underwent drug-assisted PCI in our hospital were enrolled in the study group.Plasma levels of hs-CRP,IL-6,IL-8 and fibrinogen were measured before and after treatment in both groups.Results After treatment,the levels of plasma hs-CRP,IL-6,IL-8 and fibrinogen in the study group were lower than those in the control group,the difference was statistically significant(P<0.05).The incidence of cardiovascular adverse events in the study group during the hospitalization period and within 1 year after discharge was 3.33% and 6.67%,respectively,which was lower than the control group's 20.69% and 27.59%,the difference was statistically significant(P<0.05).Conclusion The combination of drugs and PCI in the treatment of coronary artery stenosis can effectively reduce the expression levels of inflammatory factors and coagulation factors in patients' plasma,which is beneficial to further improve the prognosis of patients with this disease.

参考文献/References:

[1]于乐,解赢.冠心生脉饮对冠心病患者血清hs-CRP、IL-6、TNF-α及ICAM-1水平的影响研究[J].中国生化药物杂志,2015,12(5):108-111. [2]谢淋,丁世芳,蒋桔泉,等.不同时段PCI对STEMI患者血清hs-CRP、IL-6的影响及临床意义[J].华南国防医学杂志,2012,26(3):233-236,240. [3]刘虹,徐庆科,夏伟,等.冠心病与炎症因子IL-6、IL-8、IL-10、hs-CRP及TNF的相关性研究[J].实用心脑肺血管病杂志,2011,19(9):1446-1447. [4]李怀祥,唐朝贵.冠心病患者肺炎衣原体感染与血清超敏C反应蛋白及白介素-6表达的相关性研究[J].中华医院感染学杂志,2013,23(5):972-974. [5]于靖,曹绪芬,赵荣诚,等.不同类型老年冠心病患者外周血单核细胞程序性死亡因子配体2的表达及与血清超敏C反应蛋白、白细胞介素6的相关性[J].中国老年学杂志,2015,9(6):1563-1565.

更新日期/Last Update: 2018-07-01